Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study

 

 

 

Algernon Pharmaceuticals CEO Christopher J. Moreau joins Steve Darling from Proactive to share news regarding the positive feedback from the U.S. Food and Drug Administration at their Investigational New Drug meeting for NP-120 or Ifenprodil for the treatment of small-cell lung cancer.

Mr. Moreau explains that the feedback they received has led them to the decision to not plan any additional pre-clinical research and Algernon Pharmaceuticals will immediately move to file an application to begin a Phase 1 study as soon as possible.

Share via
Copy link
Powered by Social Snap